• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza virus characterisation report for Europe: September to December 2013 (ECDC, January 10 2014)

Giuseppe

Emeritus
[Source: European Centre for Disease Prevention and Control (ECDC), full page: (LINK).]


Influenza virus characterisation report for Europe: September to December 2013

10 Jan 2014


​The latest issue of ECDC?s series on 'Influenza virus characterisation? covers the time period since 1 September 2013.

Indicative of the late start of the 2013-14 influenza season, a low number of 46 influenza-positive specimens have been received from six EU/EEA countries so far in WHO Collaborating Centre for Reference and Research on Influenza in London.

Influenza type A viruses (91%) are dominating over type B (9%), as is often seen at the beginning of Northern Hemisphere influenza seasons. For type A, H3N2 viruses have been received in greater numbers than H1N1pdm09 viruses, with the ratio of 2:1.

The report further summarises the findings as follows:

  • Compared to the 2012?13 influenza season where genetic subgroup 6C dominated among A(H1N1)pdm09 viruses, and based on the current global situation, genetic subgroup 6B viruses have been detected in increasing frequency. Subgroup 6B viruses have been antigenically similar to the vaccine virus, A/California/07/2009.
  • Recently circulating A(H3N2) viruses have fallen within genetic subgroup 3C represented by the recommended vaccine virus for the 2013?14 season, A/Texas/50/2012; some new genetic clusters defined by specific HA amino acid substitutions have been observed for which antigenic characterisation is pending.
  • No B/Victoria-lineage viruses have been received to date.
  • Two genetic clades of B/Yamagata-lineage viruses continue to circulate: clade 3 represented by B/Wisconsin/1/2010 and clade 2 represented by B/Massachusetts/2/2012 (the recommended vaccine component for the 2013?14 influenza season). The great majority of recently circulating viruses fall within clade 2.
The report is prepared under ECDC framework contract and is based on analysis of influenza-positive specimens received by the MRC National Institute for Medical Research, the WHO Collaborating Centre for Reference and Research on Influenza in London.

For further details, download the complete report.


Read more

-
------
 
Back
Top